Analysts at H.C. Wainwright Didn’t Change their Past ‘Buy’ rating on Shares OncoSec Medical (NASDAQ:ONCS), Set a $6.0 Target Price per Share

February 15, 2018 - By Henry Gaston

 Analysts at H.C. Wainwright Didn't Change their Past ‘Buy’ rating on Shares OncoSec Medical (NASDAQ:ONCS), Set a $6.0 Target Price per Share

OncoSec Medical (NASDAQ:ONCS) Rating Reaffirmed

OncoSec Medical (NASDAQ:ONCS) just had their share rating of a ‘Buy’ issued by research analysts at H.C. Wainwright, who now has a $6.0 target on the $83.74 million market cap company or a 207.69 % upside potential. This key information was disclosed to clients in a research report on Thursday morning.

OncoSec Medical Incorporated (NASDAQ:ONCS) Ratings Coverage

Among 4 analysts covering OncoSec Medical (NASDAQ:ONCS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. OncoSec Medical has $17 highest and $500 lowest target. $5.67’s average target is 190.77% above currents $1.95 stock price. OncoSec Medical had 10 analyst reports since March 9, 2016 according to SRatingsIntel. The rating was maintained by H.C. Wainwright on Monday, June 12 with “Buy”. The firm has “Buy” rating given on Friday, June 2 by H.C. Wainwright. The firm earned “Buy” rating on Thursday, July 21 by Rodman & Renshaw. The firm earned “Buy” rating on Friday, December 15 by H.C. Wainwright. The firm has “Buy” rating by H.C. Wainwright given on Thursday, November 9. The firm has “Buy” rating given on Friday, January 19 by H.C. Wainwright. Noble Financial maintained the stock with “Buy” rating in Tuesday, June 13 report. As per Friday, June 2, the company rating was maintained by Maxim Group. H.C. Wainwright maintained OncoSec Medical Incorporated (NASDAQ:ONCS) rating on Wednesday, March 9. H.C. Wainwright has “Buy” rating and $17 target. The stock has “Buy” rating by Maxim Group on Thursday, June 8.

It closed at $1.95 lastly. It is down 34.57% since February 15, 2017 and is downtrending. It has underperformed by 51.27% the S&P500.

OncoSec Medical Incorporated, a biotechnology company, designs, develops, and commercializes gene therapies, therapeutics, and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer in the United States. The company has market cap of $83.74 million. The Company’s lead product candidate is the ImmunoPulse IL-12, which is in Phase II clinical trial for various indications, including metastatic melanoma and triple negative breast cancer. It currently has negative earnings. ImmunoPulse is an electroporation delivery device used in combination with the companyÂ’s therapeutic product candidates, including DNA plasmids that encode for immunologically active agents, and to deliver the therapeutic directly into the tumor and promote an inflammatory response against the cancer.

More notable recent OncoSec Medical Incorporated (NASDAQ:ONCS) news were published by: which released: “OncoSec Receives $9.3 Million Warrant Exercise” on November 13, 2017, also with their article: “OncoSec Medical Inc.” published on May 10, 2017, published: “OncoSec Medical Incorporated Announces Proposed Public Offering of Common Stock” on January 31, 2018. More interesting news about OncoSec Medical Incorporated (NASDAQ:ONCS) were released by: and their article: “OncoSec Appoints Daniel J. O’Connor as Chief Executive Officer to Lead Next …” published on November 07, 2017 as well as‘s news article titled: “Oncosec Medical (ONCS) Enters Warrant Exercise Agreement” with publication date: November 13, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.